Siponimod for patients with relapsing-remitting MS (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Background
Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to washout in 7 days. We aimed to determine the dose-response relation of siponimod in terms of its effects on brain MRI lesion activity and characterise safety and tolerability in patients with relapsing-remitting multiple sclerosis....... Read More - http://www.ms-uk.org/index.cfm/emergingtherapies
Siponimod for patients with relapsing-remitting MS
Siponimod for patients with relapsing-remitting MS
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 2 Replies
- 1215 Views
-
Last post by David1949
-
- 0 Replies
- 1547 Views
-
Last post by frodo
-
- 0 Replies
- 1553 Views
-
Last post by NHE
-
- 0 Replies
- 2476 Views
-
Last post by frodo
-
- 5 Replies
- 14883 Views
-
Last post by gibbledygook